

Cigna  
LS - USM - 80382  
PO Box 3050  
Easton PA 18043-3050



October 02, 2020

**Re: Changes to biosimilar coverage, effective October 1, 2020**

Earlier this year, we communicated coverage changes for oncology drugs as a result of our biosimilar strategy, which focuses on clinical safety and efficacy as well as a patient's condition and duration of therapy to determine lower-cost coverage options for our customers.

Effective October 1, 2020, we will add KANJINTI™ to our preferred list of trastuzumab biosimilars, which already includes Ogivri™ and TRAZIMERA. Customers who are new to therapy and request a nonpreferred trastuzumab product, including Herceptin®/Herceptin Hylecta™, HERZUMA®, and ONTRUZANT®, will be required to use one of the preferred products to obtain coverage.\*

If you have any questions, please call Cigna Customer Service at **800.88Cigna (882.4462)** or contact your local Cigna Medical Market Executive.

Sincerely,

A handwritten signature in cursive script that reads "Young Fried".

Young Fried, PharmD, MSP  
Chief Pharmacy Officer, Cigna Pharmacy Management®

\* If a provider believes any of the products that will no longer be covered as preferred options are medically necessary, Cigna will review requests for a medical necessity exceptions. Providers can submit requests for medical necessity review through their electronic health record or electronic medical record system or through CoverMyMeds® or Surescripts®.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. PCOMM-2020-871

974950683601